LTRN Lantern Pharma Inc
Price (delayed)
$3.42
Market cap
$36.88M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.93
Enterprise value
$29.62M
Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. It leverages advances in machine learning, genomics, and artificial intelligence by
Highlights
The company's debt fell by 16% QoQ but it rose by 3.9% YoY
The quick ratio has plunged by 64% YoY and by 29% from the previous quarter
The equity has contracted by 48% YoY and by 20% from the previous quarter
Key stats
What are the main financial stats of LTRN
Market
Valuations
Earnings
Shares outstanding
10.78M
Market cap
$36.88M
Enterprise value
$29.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.74
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$22.22M
Net income
-$20.78M
EBIT
-$20.78M
EBITDA
-$20.59M
Free cash flow
-$17.83M
Per share
Balance sheet
Liquidity
EPS
-$1.93
EPS diluted
-$1.93
Free cash flow per share
-$1.66
Book value per share
$1.96
Revenue per share
$0
TBVPS
$2.38
Total assets
$25.57M
Total liabilities
$4.38M
Debt
$243,657
Equity
$21.19M
Working capital
$20.92M
Debt to equity
0.01
Current ratio
5.83
Quick ratio
5.54
Net debt/EBITDA
0.35
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-63.4%
Return on equity
-72.6%
Return on invested capital
-121%
Return on capital employed
-97.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LTRN stock price
How has the Lantern Pharma stock price performed over time
Intraday
3.32%
1 week
-6.3%
1 month
-13.42%
1 year
-62.62%
YTD
7.21%
QTD
-3.39%
Financial performance
How have Lantern Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$22.22M
Net income
-$20.78M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 30% YoY and by 9% QoQ
The operating income has declined by 24% year-on-year and by 4.8% since the previous quarter
Growth
What is Lantern Pharma's growth rate over time
Valuation
What is Lantern Pharma stock price valuation
P/E
N/A
P/B
1.74
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Lantern Pharma's EPS has decreased by 31% YoY and by 8% from the previous quarter
The equity has contracted by 48% YoY and by 20% from the previous quarter
LTRN's price to book (P/B) is 16% lower than its 5-year quarterly average of 2.0 and 7% lower than its last 4 quarters average of 1.8
Efficiency
How efficient is Lantern Pharma business performance
The ROE has plunged by 113% YoY and by 28% from the previous quarter
Lantern Pharma's return on assets has shrunk by 97% YoY and by 24% QoQ
The return on invested capital has dropped by 50% year-on-year and by 17% since the previous quarter
Dividends
What is LTRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LTRN.
Financial health
How did Lantern Pharma financials performed over time
The current ratio has dropped by 64% year-on-year and by 30% since the previous quarter
The quick ratio has plunged by 64% YoY and by 29% from the previous quarter
The company's debt is 99% lower than its equity
The equity has contracted by 48% YoY and by 20% from the previous quarter
The company's debt fell by 16% QoQ but it rose by 3.9% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.